FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Neutropenia
• Neutropenia
• Neutropenia Following Bone Marrow Transplantation

Drugs mentioned

• Neupogen (Filgrastim)

Snippet

SUPPL AP for NEUPOGEN (FILGRASTIM)